| AS04 | Aluminum salt plus 3-O-desacyl-4′-monophosphoryl lipid A |
| BNLF-1 MA | BamHI N leftward reading frame 1 membrane antigen |
| CpG | Cytosine–phosphate–guanine |
| ODN | Oligodeoxynucleotide |
| CR2BS | Complement receptor 2 binding site |
| EBNA | Epstein–Barr nuclear antigen |
| EBV | Epstein–Barr virus |
| ELISA | Enzyme-linked immunosorbent assay |
| EphA2 | Ephrin receptor tyrosine kinase A2 |
| FDA | Food and Drug Administration |
| FLR | FLRGRAYGL peptide |
| gB | Glycoprotein B |
| gH | Glycoprotein H |
| gL | Glycoprotein L |
| gp110 | Glycoprotein 110 |
| gp220 | Glycoprotein 220 |
| gp350 | Glycoprotein 350 |
| gp42 | Glycoprotein 42 |
| H. pylori | Helicobacter pylori |
| HLA | Human leukocyte antigen |
| IM | Infectious mononucleosis |
| LMP | Latent membrane protein |
| mAbs | Monoclonal antibodies |
| MPL | Monophosphoryl lipid |
| NHP | Non-human primates |
| NPC | Nasopharyngeal carcinoma |
| NPs | Nanoparticles |
| SAS | Sigma adjuvant system |
| TCR | T cell receptor |
| Th cells | T helper cells |
| VV | Vaccinia virus |